MVRIX Co., Ltd

MVRIX Co., LTD is a forward-thinking biotechnology company dedicated to pushing the boundaries of therapeutic innovation. With a strong commitment to collaboration and growth, we actively seek partnerships with industry leaders, universities, and research institutions to advance joint research and accelerate the development of transformative solutions. Our work focuses on three core platform technologies: Recombinant Botulinum Toxin, Grab-body, and Virucidal Therapeutics. Through our Recombinant Botulinum Toxin platform, we’re setting a new standard in engineered toxins with enhanced safety, efficacy, and adaptability for various medical applications. Grab-body, our proprietary targeted mRNA delivery system, empowers precise therapeutic targeting while enabling scalable, cost-effective mass production—bringing advanced therapies in mRNA therapeutics, Cancer vaccine, and In vivo CAR-T. Additionally, our Virucidal Therapeutics platform introduces the first-in-class approach to virus treatment by physically dismantling viruses, offering a mutation-resistant solution to tackle diverse infectious diseases. At MVRIX, we are driven by a commitment to innovation, versatile solutions, and creating a positive impact. Our vision is to develop pioneering technologies that redefine possibilities in biotech and deliver tangible benefits for health worldwide. Learn more about us at www.mvrix.co.kr